• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    1/5/24 4:39:59 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care
    Get the next $ALPA alert in real time by email
    8-K
    false000184293900018429392023-12-292023-12-290001842939us-gaap:WarrantMember2023-12-292023-12-290001842939us-gaap:CommonStockMember2023-12-292023-12-29

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 29, 2023

     

     

    Carmell Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40228

    86-1645738

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2403 Sidney Street, Suite 300

     

    Pittsburgh, Pennsylvania

     

    15203

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 281 297-8276

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    CTCX

     

    The Nasdaq Stock Market LLC

    Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

     

    CTCXW

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On December 29, 2023, Carmell Corporation ("Company") entered into an employment agreement with Rajiv Shukla, the Company's Chief Executive Officer (the “Employment Agreement”). Pursuant to the Employment Agreement, Mr. Shukla will receive total annual compensation of $425,000, which may be adjusted from time to time by the Compensation Committee of the Company’s Board of Directors (“Compensation Committee”). Mr. Shukla's annual compensation is payable as follows: 75% in cash in accordance with the Company's standard payroll schedule and 25% payable quarterly in arrears in the form of fully vested shares of the Company's common stock based on the average daily price of the Company’s common stock for the quarter immediately preceding and ending on the date of grant.

    In addition, Mr. Shukla has the opportunity to earn an annual bonus with a target of 50% of his total annual compensation in effect at the end of the applicable year. The amount of such annual bonus will be solely determined by the Company's Board of Directors based on the satisfactory achievement of corporate and/or personal objectives set by the Compensation Committee. Such annual bonus, if any, will be paid as follows: 75% in cash and 25% in the form of fully vested shares of the Company's common stock based on the average daily price of the Company’s common stock for the quarter immediately preceding and ending on the date of grant.

     

    The Employment Agreement provides that Mr. Shukla is entitled to certain severance payments in connection with a termination of employment by the Company without Cause (as defined in the Employment Agreement) or by Mr. Shukla for Good Reason (as defined in the Employment Agreement) (each such termination, a “Qualifying Termination”), subject to his timely execution of a release of claims. If a Qualifying Termination occurs within three months prior or 18 months following a Change in Control (defined as a “Protected Period” in the Employment Agreement), Mr. Shukla would be entitled to receive monthly cash severance payments equal to one-twelfth of his annual salary for an 18-month period. If a Qualifying Termination occurs other than during the Protected Period, then Mr. Shukla would be entitled to receive such monthly cash severance payments for a 12-month period. In the event of a Qualifying Termination, Mr. Shukla would also be entitled to receive his compensation, including any bonus award already accrued, payment of a portion of COBRA premiums for him and his eligible dependents and a Pro Rata Bonus (as defined in the Employment Agreement) based upon actual performance and pro-rated for the portion of the bonus period prior to termination. In the event that such a Qualifying Termination occurs during a Protected Period, Mr. Shukla would be entitled to receive his bonus at target level, as well as accelerated vesting of time-based equity awards, as more fully described in the Employment Agreement.

     

    In connection with a termination of his employment for any other reason, Mr. Shukla would only be entitled to receive his compensation that has already accrued, provided that he would only be entitled to receive his accrued and unpaid bonus in connection with termination for death or disability.

     

    The Employment Agreement also requires Mr. Shukla to enter into a restrictive covenants agreement that contains customary covenants, including with respect to certain confidentiality, non-competition and non-solicitation obligations.

     

    The foregoing description is not complete and is qualified in its entirety by the text of the full Employment Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following exhibit is filed as part of this report:

     

    Exhibit

    Number Description

     

    10.1 Executive Employment Agreement between Carmell Corporation and Rajiv Shukla, dated December 29, 2023

     

     

     

     

     

     

     

     

     

     


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Carmell Corporation

     

     

     

     

    Date:

    January 5, 2024

    By:

    /s/ Bryan J. Cassaday

     

     

     

    Chief Financial Officer

     

     


    Get the next $ALPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Healthcare Acquisition Corp. III Announces Successful Closing of Business Combination with Carmell Therapeutics Corporation

    Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the successful completion of its business combination (the "Business Combination") with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). The resulting combined company, Carmell Therapeutics Corporation, is expected to commence trading of its shares of common stock and warrants on the Nasdaq Capital Market® under the ticker symbols "CTCX" and "CTCXW," respectively, on July 17, 2023.

    7/14/23 3:12:00 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III Announces Non-Binding Letter of Intent to Acquire a Commercial Stage Regenerative Medicine Company Conditioned Upon Closing of Carmell Business Combination

    Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a non-binding letter of intent (the "LOI") to acquire a commercial stage regenerative medicine company (the "Target") conditioned upon the closing of ALPA's initial business combination with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). ALPA has set a Stockholders Meeting (the "Meeting") to consider the previously announced business combination with Carmell for J

    6/27/23 7:00:00 AM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic Plasma-based Biomaterials for Bone and Soft Tissue Healing Indications

    Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement with Carmell Therapeutics Corporation ("Carmell™"), a Phase 2-stage biotechnology platform company developing allogeneic plasma-based biomaterials for bone and soft tissue healing indications. Upon closing of the transaction, ALPA will be renamed Carmell Therapeutics Corporation (the "Combined Company"). Mr. Shukla will serve as Chairman and Mr. Randy Hubbell will serve as Chief Executive Officer of the Combined Company. The Combined Company's common stock is expected to be listed on the Na

    1/4/23 10:11:00 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Shukla Rajiv was granted 14,347 shares and acquired 0 shares, increasing direct ownership by 42% to 48,526 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    1/4/24 9:17:09 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Cassaday Bryan J. bought $1,540 worth of shares (440 units at $3.50), increasing direct ownership by 29% to 1,940 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/19/23 5:00:05 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Spenlehauer Gilles bought $3,456 worth of shares (904 units at $3.82) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/18/23 5:13:12 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cassaday Bryan J. bought $1,540 worth of shares (440 units at $3.50), increasing direct ownership by 29% to 1,940 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/19/23 5:00:05 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Spenlehauer Gilles bought $3,456 worth of shares (904 units at $3.82) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/18/23 5:13:12 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Frisch Scott M. bought $3,456 worth of shares (904 units at $3.82) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/18/23 5:12:55 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    SEC Filings

    View All

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Carmell Corp (0001842939) (Filer)

    1/16/24 7:27:40 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Carmell Corp (0001842939) (Filer)

    1/16/24 7:14:47 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Carmell Corp (0001842939) (Filer)

    1/16/24 7:07:47 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    2/14/24 4:13:13 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    2/14/24 3:42:33 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III

    SC 13G - Carmell Corp (0001842939) (Subject)

    2/14/24 12:54:27 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care